A National Consensus Survey for Current Practicein Brain Tumor Management I: Antiepileptic Drug andSteroid Usage
- Author:
Sung Kwon KIM
1
;
Jangsup MOON
;
Jin Mo CHO
;
Kyung Hwan KIM
;
Se Hoon KIM
;
Young Il KIM
;
Young Zoon KIM
;
Ho Sung KIM
;
Yun-Sik DHO
;
Jae-Sung PARK
;
Ji Eun PARK
;
Youngbeom SEO
;
Kyoung Su SUNG
;
Jin Ho SONG
;
Chan Woo WEE
;
Wan-Soo YOON
;
Hong In YOON
;
Se-Hoon LEE
;
Do Hoon LIM
;
Jung Ho IM
;
Jong Hee CHANG
;
Myung-Hoon HAN
;
Je Beom HONG
;
Kihwan HWANG
;
Chul-Kee PARK
;
Youn Soo LEE
;
Ho-Shin GWAK
;
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:Brain Tumor Research and Treatment 2020;8(1):1-10
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:: The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO)conducted a nationwide questionnaire survey for diverse queries faced in the treatment of brain tumors.As part I of the survey, the aim of this study is to evaluate national patterns of clinical practiceabout antiepileptic drug (AED) and steroid usage for management of brain tumors.
Methods:: A web-based survey was sent to all members of the KSNO by email. The survey included9 questions of AED usage and 5 questions of steroid usage for brain tumor patients. All questionswere developed by consensus of the Guideline Working Group.
Results:: The overall response rate was 12.8% (54/423). Regarding AED usage, the majority ofrespondents (95.2%) routinely prescribed prophylactic AEDs for patients with seizure at the peri/postoperativeperiod. However, as many as 72.8% of respondents prescribed AED routinely for seizure-naïvepatients, and others prescribed AED as the case may be. The duration of AED prophylaxis showedwide variance according to the epilepsy status and the location of tumor. Levetiracetam (82.9%) wasthe most preferred AED for epilepsy prophylaxis. Regarding steroid usage, 90.5% of respondents usesteroids in perioperative period, including 34.2% of them as a routine manner. Presence of peritumoraledema (90.9%) was considered as the most important factor determining steroid usage followed bydegree of clinical symptoms (60.6%). More than half of respondents (51.2%) replied to discontinue thesteroids within a week after surgery if there are no specific medical conditions, while 7.3% preferredslow tapering up to a month after surgery.
Conclusion:: The survey demonstrated the prevailing practice patterns on AED and steroid usagein neuro-oncologic field among members of the KSNO. This information provides a point of referencefor establishing a practical guideline in the management of brain tumor patients.
